Visby Medical is a technology company.
Visby Medical has raised $325.0M across 4 funding rounds.
Visby Medical has raised $325.0M in total across 4 funding rounds.
Visby Medical has raised $325.0M in total across 4 funding rounds.
Visby Medical's investors include Alumni Ventures, General Catalyst, Greylock, Innovation Endeavors, Kleiner Perkins, LGF, Kenneth Griffin, Highbury Group.
Visby Medical is a health technology company developing instrument-free, single-use PCR diagnostic devices for rapid point-of-care and at-home testing of infectious diseases, primarily sexually transmitted infections (STIs) like chlamydia, gonorrhea, and trichomoniasis, as well as respiratory illnesses such as COVID-19, flu A, and flu B.[1][2][3][4][5] It serves healthcare providers in CLIA-waived settings, clinics, urgent care, and consumers via at-home kits, solving the problem of delayed diagnosis by enabling results in under 30 minutes without lab equipment or mailing samples, which supports immediate "test-to-treat" decisions and improves patient outcomes.[2][3][4][5][6] The company demonstrates strong growth momentum, including FDA clearances, De Novo authorizations, federal grants like CARB-X funding, and a recent up-to-$65 million financing round in 2025 to accelerate at-home STI test launches.[4][5][7]
Founded in 2012 in San Jose, California, by Adam de la Zerda, PhD, Visby Medical emerged from a vision to revolutionize infectious disease diagnostics using proprietary PCR technology that eliminates the need for bulky instruments.[3][5][7] De la Zerda, drawing on his expertise in biomedical engineering, created the world's first palm-sized, disposable PCR platform to enable single-visit test-and-treat workflows for clinicians.[4] Early traction came through FDA 510(k) clearances and CLIA waivers for its Sexual Health Test targeting the three most common curable STIs in women, followed by expansions into men's urine-based testing via CARB-X funding and respiratory panels amid the COVID-19 pandemic.[4][5][6] Pivotal moments include federal grants for antibiotic stewardship diagnostics and the 2025 financing led by Catalio Capital Management to launch consumer at-home products.[4][7]
Visby Medical stands out in the diagnostics market through these key advantages:
Visby Medical rides the wave of decentralized diagnostics and consumer health empowerment, accelerated by pandemic-driven demand for rapid, point-of-care testing and rising STI rates (e.g., chlamydia, gonorrhea, trichomoniasis as top U.S. curable infections).[3][4][5] Timing is ideal amid growing antibiotic resistance concerns—CARB-X funding highlights its role in stewardship by enabling precise treatment—and telehealth normalization, which its integrated model leverages for privacy-focused care.[4][7] Favorable market forces include FDA's push for OTC molecular tests and direct-to-consumer channels, positioning Visby to disrupt a fragmented $10B+ diagnostics sector dominated by slow lab methods.[3][5][7] It influences the ecosystem by pioneering at-home PCR, inspiring scalable solutions for underserved areas and reducing healthcare burdens through faster interventions.[1][2][4]
Visby Medical is poised to dominate at-home STI testing with its July 2025 direct-to-consumer launch in select U.S. cities, backed by $65M funding for platform expansion into more infections and markets.[3][7] Trends like AI-enhanced telehealth integration, global AMR battles, and consumer demand for privacy will propel growth, potentially evolving it from point-of-care innovator to full-spectrum self-care diagnostics leader. Watch for international scaling and male/female respiratory at-home kits, amplifying its "test-to-treat" disruption in a post-pandemic world.[4][7] This palm-sized revolution returns power to patients, fulfilling its founding promise to eliminate diagnostic delays.[1][3]
Visby Medical has raised $325.0M across 4 funding rounds. Most recently, it raised $55.0M Venture Round in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $55.0M Venture Round | Alumni Ventures, General Catalyst, Greylock, Innovation Endeavors, Kleiner Perkins, LGF, Kenneth Griffin | |
| Feb 1, 2022 | $100.0M Series E | Alumni Ventures, General Catalyst, Greylock, Innovation Endeavors, Kleiner Perkins, LGF, Kenneth Griffin | |
| May 1, 2020 | $70.0M Series D | Alumni Ventures, General Catalyst, Greylock, Innovation Endeavors, Kleiner Perkins, LGF, Kenneth Griffin | |
| Apr 1, 2019 | $100.0M Series C | Highbury Group |